Yahoo Web Search

Search results

1. www.biopharmadive.com › news › lilly-acquireLilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com › news › lilly-acquire

   • Cached

   Jun 29, 2023 · Dive Brief: Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday.

2. www.emergentbiosolutions.com › press › news-releaseStatement on Issuance of Form FDA 483 at Emergent Bayview ...

   www.emergentbiosolutions.com › press › news-release

   • Cached

   GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore-Bayview facility and provided specific feedback.

3. www.bioworld.com › articles › 514047-aiming-to-buildAiming to build a better ADC, Emergence raises $98M in series A

   www.bioworld.com › articles › 514047-aiming-to-build

   • Cached

   Dec 7, 2021 · LONDON – Europe’s latest antibody-drug conjugate (ADC) specialist, Emergence Therapeutics AG, will be going head to head with pioneer Seagen Inc.’s approved ADC, Padcev, after raising €87 million (US$97.9 million) in a series A round.

4. www.businesswire.com › news › homeMablink Bioscience and Emergence Therapeutics Enter Into a ...

   www.businesswire.com › news › home

   • Cached

   Oct 21, 2021 · Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s PSARlink™ drug-linker technology.

5. www.globenewswire.com › news-release › 2021/12/07Emergence Therapeutics raises €87 million Series A

   www.globenewswire.com › news-release › 2021/12/07

   • Cached

   Dec 7, 2021 · Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an...

6. www.marketscreener.com › news › latestEmergence Therapeutics raises €87 million Series A financing ...

   www.marketscreener.com › news › latest

   • Cached

   Dec 7, 2021 · Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round.

7. People also ask

   Who is emergence Therapeutics?

   • Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology.

   Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing …

   www.businesswire.com/news/home/20211021005064/en/Mablink-Bioscience-and-Emergence-Therapeutics-Enter-Into-a-Licensing-Agreement-to-Develop-Antibody-Drug-Conjugate-as-a-Potential-Cancer-Therapy

   See all results for this question

   Will emergence Therapeutics raise €87 million Series A financing for nectin-4 ADC?

   • Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC Duisburg, Germany, 7 December 2021.

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

   Where is emergent based?

   • Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit:

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

   Is Eli Lilly acquiring emergence Therapeutics?

   • Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday. In a short statement, European cancer drug developer and founding Emergence investor Heidelberg Pharma said Lilly is acquiring all of the startup’s shares.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

   Why did emergence Therapeutics invest in an oversubscribed ADC round?

   • Proceeds from the financing will also support the development of a pipeline of further ADC candidates. Jack Elands, CEO of Emergence Therapeutics, commented: “The completion of this significantly oversubscribed round enables Emergence to execute on its strategy to become a dominant ADC developer.

   Emergence Therapeutics raises €87 million Series A - GlobeNewswire

   www.globenewswire.com/news-release/2021/12/07/2347055/0/en/Emergence-Therapeutics-raises-87-million-Series-A-financing-to-advance-Nectin-4-ADC.html

   See all results for this question

   Who owns emergence Therapeutics & sigilon Therapeutics?

   • The company on Thursday announced plans to acquire cell therapy developer Sigilon Therapeutics for up to $310 million, and previously announced a $2.4 billion deal to buy inflammatory disease drugmaker Dice Therapeutics. In addition to Heidelberg, Emergence is backed by Pontifax Venture Capital, RA Capital Management and OrbiMed.

   Lilly to acquire cancer antibody drug startup Emergence

   www.biopharmadive.com/news/lilly-acquire-emergence-adc-cancer-drugs/654326/

   See all results for this question

8. www.crunchbase.com › funding_round › emergenceSeries A - Emergence Therapeutics - 2021-12-07 - Crunchbase

   www.crunchbase.com › funding_round › emergence

   • Cached

   Dec 7, 2021 · News • Jul 12, 2021. emergencetx.com — Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC.